Induction of NK cell reactivity against AML and CLL cells by Fc-engineered GITR-Fc fusion proteins

被引：0
|
作者：
Hilpert, J. [1 ]
Schmiedel, B. J. [1 ]
Werner, A. [1 ]
Nuebling, T. [1 ]
Buechele, C. [1 ]
Grosse-Hovest, L. [2 ]
Kanz, L. [1 ]
Salih, H. R. [1 ]
机构：
[1] Univ Tubingen, Dept Hematol & Oncol, Tubingen, Germany
[2] Univ Tubingen, Dept Immunol, Tubingen, Germany
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：57 / 58
页数：2
相关论文
共 50 条
  • [21] Induction of NK Cell Reactivity Against Myeloid Leukemia By a Novel Fc-Optimized CD133 Antibody
    Rothfelder, Kathrin
    Koerner, Samuel
    Andre, Maya
    Leibold, Julia
    Kousis, Philaretos
    Buehring, Hans-Joerg
    Haen, Sebastian P.
    Kuebler, Ayline
    Kanz, Lothar
    Grosse-Hovest, Ludger
    Jung, Gundram
    Salih, Helmut R.
    BLOOD, 2015, 126 (23)
  • [22] Induction of NK cell reactivity against myeloid leukemia by a novel Fc-optimized CD133 antibody
    Rothfelder, K.
    Koerner, S.
    Leibold, J.
    Kousis, P.
    Buehring, H-J
    Haen, S.
    Kuebler, A.
    Andre, M.
    Jung, G.
    Kanz, L.
    Grosse-Hovest, L.
    Salih, H. R.
    Oncology Research and Treatment, 2015, 38 : 259 - 259
  • [23] An Fc-engineered CD19 antibody engages NK cells and macrophages and is effective in Xenograft models of acute lymphoblastic leukemia
    Kellner, C.
    Alsadeq, A.
    Cario, G.
    Vieth, S.
    Rosskopf, S.
    Burmeister, Y.
    Klausz, K.
    Valerius, T.
    Schrappe, M.
    Gramatzki, M.
    Peipp, M.
    Schewe, D. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 202 - 202
  • [24] An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia
    Riegg, Fabian
    Lutz, Martina S.
    Schmied, Bastian J.
    Heitmann, Jonas S.
    Queudeville, Manon
    Lang, Peter
    Jung, Gundram
    Salih, Helmut R.
    Maerklin, Melanie
    CANCERS, 2021, 13 (07)
  • [25] B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
    Hagelstein, Ilona
    Engel, Monika
    Hinterleitner, Clemens
    Manz, Timo
    Maerklin, Melanie
    Jung, Gundram
    Salih, Helmut R.
    Zekri, Latifa
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies
    Chu, Seung Y.
    Vostiar, Igor
    Karki, Sher
    Moore, Gregory L.
    Lazar, Greg A.
    Pong, Erik
    Joyce, Patrick F.
    Szymkowski, David E.
    Desjarlais, John R.
    MOLECULAR IMMUNOLOGY, 2008, 45 (15) : 3926 - 3933
  • [27] Induction of NK Cell Reactivity against B-Cell Acute Lymphoblastic Leukemia by an Fc-Optimized FLT3 Antibody
    Schmied, Bastian J.
    Lutz, Martina S.
    Riegg, Fabian
    Zekri, Latifa
    Heitmann, Jonas S.
    Buehring, Hans-Joerg
    Jung, Gundram
    Salih, Helmut R.
    CANCERS, 2019, 11 (12)
  • [28] Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia
    Koerner, Samuel
    Leibold, Julia
    Grosse-Hovest, Ludger
    Buehring, Hans-Joerg
    Jung, Gundram
    Kanz, Lothar
    Salih, Helmut R.
    BLOOD, 2014, 124 (21)
  • [29] Generation and preclinical characterization of an Fc-optimized CD133 antibody for improved induction of NK cell reactivity against myeloid leukemia
    Koerner, S.
    Leibold, J.
    Grosse-Hovest, L.
    Buehring, H. -J
    Kanz, L.
    Jung, G.
    Salih, H.
    ONKOLOGIE, 2013, 36 : 271 - 271
  • [30] Generation and preclinical characterization of an Fc-optimized CD133 antibody for improved induction of NK cell reactivity against solid tumors
    Koerner, S.
    Leibold, J.
    Grosse-Hovest, L.
    Buehring, H-J
    Jung, G.
    Kanz, L.
    Salih, H. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 112 - 112
12345